Example: Heart Attack

Search clinical trials for: BCG Vaccine

Total 315 results

NCT04498702

Completed

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

Conditions: Non-muscle Invasive Bladder Cancer
NCT04496219

Not yet recruiting

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Conditions: Bladder Urothelial Carcinoma In Situ; Recurrent Bladder Urothelial Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8; Superficial Bladder Urothelial Carcinoma
NCT04493489

Not yet recruiting

Propranolol Adjuvant Treatment of Bladder Cancer

Conditions: Bladder Cancer
NCT04475302

Recruiting

BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots

Conditions: COVID
NCT04461379

Not yet recruiting

Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers

Conditions: BCG; COVID-19; SARS-CoV2; Corona Virus Infection
NCT04453293

Not yet recruiting

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

Conditions: Tuberculosis Infection
NCT04452591

Not yet recruiting

Study of CG0070 Given in Patients With Non-Muscular Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Conditions: Non Muscular Invasive Bladder Cancer
NCT04449926

Not yet recruiting

BCG and Plasma Amyloid in Non-Demented Adults

Conditions: Alzheimer Disease, Late Onset
NCT04439045

Not yet recruiting

Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

Conditions: SARS-CoV-2 Infection
NCT04435379

Recruiting

Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

Conditions: Infection, Respiratory Tract
NCT04414267

Recruiting

Bacillus Calmette-guérin Vaccination to Prevent COVID-19

Conditions: COVID-19; Virus Diseases; Corona Virus Infection; Coronary Heart Disease; Chronic Obstructive Pulmonary Disease
NCT04417335

Active, not recruiting

Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination

Conditions: COVID-19
NCT04412070

Not yet recruiting

Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients

Conditions: Bladder Cancer
NCT04386746

Recruiting

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

Conditions: Urothelial Carcinoma Bladder; Bladder Cancer
NCT04387409

Recruiting

Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Conditions: Infection, Respiratory Tract
NCT04387461

Not yet recruiting

Study of CG0070 Given in Combination With Pembrolizumab, in Non Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Conditions: Non Muscle Invasive Bladder Cancer
NCT04383925

Recruiting

Trial to Compare Two Strains of BCG

Conditions: Death, Infant; Morbidity;Infant
NCT04384549

Not yet recruiting

Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers

Conditions: Infection; Viral, Agent as Cause of Disease Classified Elsewhere
NCT04384614

Not yet recruiting

Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study

Conditions: Covid 19; BCG Vaccination
NCT04379336

Recruiting

BCG Vaccination for Healthcare Workers in COVID-19 Pandemic

Conditions: COVID-19; Sars-CoV2
NCT04373291

Not yet recruiting

Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic

Conditions: COVID-19; Non-specific Effects of Vaccines; Morbidity; Absenteeism; Heterologous Immunity
NCT04369794

Recruiting

COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement

Conditions: COVID-19; Therapeutic Vaccine; BCG; SARS-CoV 2; Transmission
NCT04362124

Not yet recruiting

Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection

Conditions: COVID-19
NCT04350931

Not yet recruiting

Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19

Conditions: Coronavirus Disease (COVID-19)
NCT04351685

Not yet recruiting

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

Conditions: Mycobacterium Tuberculosis Infection
NCT04348370

Recruiting

BCG Vaccine for Health Care Workers as Defense Against COVID 19

Conditions: Coronavirus; Coronavirus Infection; Coronavirus as the Cause of Diseases Classified Elsewhere
NCT04347876

Recruiting

Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?

Conditions: COVID-19; BCG Vaccination
NCT04327206

Recruiting

BCG Vaccination to Protect Healthcare Workers Against COVID-19

Conditions: Coronavirus Disease 2019 (COVID-19); Respiratory Illness; Corona Virus Infection; COVID-19
NCT04328441

Recruiting

Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine

Conditions: COVID-19
NCT04319263

Completed

Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer

Conditions: Bladder Cancer
NCT04311580

Completed

Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure

Conditions: Bladder Cancer
NCT04298073

Not yet recruiting

Skipping BCG for T1a Urinary Bladder Tumor.

Conditions: Superficial Bladder Cancer t1a
NCT04256122

Recruiting

Expression of Markers Related to Mitochondrial Functionality in Carcinoma of the Urinary Bladder: Comparative Retrospective Analysis Between Recurrent Tumors ("Non-responders") and Non-recurrent Tumors ("Responders") After Intravesical Treatment With Chemotherapy or Immunotherapy

Conditions: Bladder Cancer
NCT04179162

Recruiting

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Conditions: Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT04172675

Recruiting

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Conditions: Urinary Bladder Neoplasms
NCT04164082

Suspended

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Conditions: Bladder Urothelial Carcinoma In Situ; Infiltrating Bladder Mixed Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8
NCT04165317

Recruiting

Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

Conditions: Non-muscle Invasive Bladder Cancer
NCT04152161

Recruiting

BCG Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection

Conditions: Tuberculosis
NCT04149574

Recruiting

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Conditions: Bladder Cancer
NCT04142359

Recruiting

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)

Conditions: Pharmacokinetics
NCT04134000

Not yet recruiting

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Conditions: Invasive Bladder Cancer
NCT04121494

Recruiting

ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039)

Conditions: Mycobacterium Tuberculosis, Protection Against; Tuberculosis
NCT04109092

Recruiting

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Conditions: Urinary Bladder Neoplasms
NCT04106115

Not yet recruiting

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Conditions: Bladder Cancer
NCT04073160

Withdrawn

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer

Conditions: Bladder Cancer
NCT04064554

Completed

Clinical Study to Evaluate Safety and Immunogenicity of Bacillus Calmette-Guerin (BCG) Delivery Via Novel Micronjet600 Device Compared to Those Via Conventional Needle

Conditions: Tuberculosis; BCG Vaccination
NCT04040725

Withdrawn

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Conditions: Bladder Cancer
NCT03982797

Recruiting

Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis

Conditions: Bladder Cancer
NCT03950362

Not yet recruiting

Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer

Conditions: Non-muscle-invasive Bladder Cancer
NCT03947138

Not yet recruiting

A Study of GC3107(BCG Vaccine) in Healthy Infants

Conditions: BCG Vaccination Reaction; Tuberculosis

Search clinical trials for: BCG Vaccine

Recent CRA jobs

Scientist - BioAnalytics

Finance Assistant (6 months internship)

Digital Implementation Manager - eCOA (remote)

Sr CM Analyst I

Project Manager - Central Lab

Shipping/ Receiving Coordinator

Associate Scientist / Scientist - GMP , Pilot Plant , Small Molecule

Principal Database Programmer (UK, Spain, Romania, Poland, Ireland)

Global Category Sourcing Manager - Clinical Lab

Clinical Research Physician